文献速递其他结缔组织病

系统性硬化症患者COVID-19的严重程度与死亡率:一项巴西多中心研究

Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study.
PubMed 文献 · Semin Arthritis Rheum · 2022-02-25

该巴西多中心回顾性观察研究纳入2020年3月至2021年6月圣保罗四中心随访的1042例系统性硬化症(SSc)患者,其中118例诊断为COVID-19,66.1%为轻型、33.9%为中重型、5.1%死亡。多因素分析仅SSc相关间质性肺病(SSc-ILD)与中重型COVID-19风险升高显著相关(OR 2.73,95%CI 1.12-6.69,p=0.02)。

要点

  • 118例SSc合并COVID-19患者中,轻型78例(66.1%),中重型40例(33.9%),死亡6例(5.1%)。
  • 多因素分析仅SSc-ILD与中重型COVID-19风险升高显著相关(OR 2.73,95%CI 1.12-6.69,p=0.02)。
  • 40%的患者在COVID-19后仍残留症状,以呼吸困难(17%)和/或咳嗽为主。

核心结论

  • 在该SSc队列中,合并SSc-ILD的患者受COVID-19影响较大,中重型COVID-19感染和死亡风险更高。

研究设计与样本

  • 多中心、回顾性、观察性研究,纳入2020年3月至2021年6月圣保罗四中心随访的1042例SSc患者。
  • COVID-19诊断依据为RT-PCR阳性或高度疑似感染,按轻型(门诊治疗且无需氧疗)和中重型(住院和/或需氧疗)分组。

主要发现

  • 1042例SSc患者中118例诊断为COVID-19,其中轻型78例(66.1%)、中重型40例(33.9%),死亡6例(5.1%)。
  • SSc-ILD存在于总队列的65.6%和合并COVID-19的SSc患者的46.3%。
  • 单因素分析中,肺动脉高压(OR 9.50,p=0.006)、SSc-ILD(OR 3.90,p=0.007)、FVC<80%(OR 2.90,p=0.01)、心脏受累(OR 5.53,p=0.003)和使用利妥昔单抗(OR 3.92,p=0.039)为COVID-19不良结局的预测因素,而年龄、性别、合并症或使用糖皮质激素不是。
  • 多因素分析中,仅SSc-ILD与中重型COVID-19风险升高显著相关(OR 2.73,95%CI 1.12-6.69,p=0.02)。
  • 40%的患者在COVID-19后仍残留症状,以呼吸困难和/或咳嗽为主(17%)。

关键数值与推荐

  • 中重型COVID-19定义为住院和/或需要氧疗,轻型定义为门诊治疗且无需氧疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: COVID-19 may be associated with greater severity and mortality in patients with systemic sclerosis (SSc). The present study aimed to evaluate the prevalence, severity and mortality of COVID-19 in a Brazilian cohort of SSc patients. METHODS: This multicenter, retrospective, observational study included 1,042 SSc patients followed in four centers of São Paulo between March 2020 and June 2021. Diagnosis of COVID-19 was established by proper positive RT-PCR testing or by highly suspicious infection. Patients were grouped into mild (outpatient setting treatment and no need for oxygen support) and moderate-to-severe (hospitalization and/or need for oxygen support) COVID-19. RESULTS: Of the 1,042 SSc patients, 118 patients were diagnosed with COVID-19. Interstitial lung disease (SSc-ILD) was present in 65.6% of the total cohort and in 46.3% of SSc patients with COVID-19. There were 78 (66.1%) cases of mild COVID-19, and 40 (33.9%) cases of moderate-to-severe disease, with 6 (5.1%) deaths. By univariate analysis, pulmonary arterial hypertension (OR 9.50, p=0.006), SSc-ILD (OR 3.90, p=0.007), FVC <80% (OR 2.90, p=0.01), cardiac involvement (OR 5.53, p=0.003), and use of rituximab (OR 3.92, p=0.039), but not age, gender, comorbidities or use of corticosteroids, were predictors of worse outcome for COVID-19. Using multivariate analysis, only SSc-ILD was significantly associated to a higher risk of moderate-to-severe COVID-19 (OR 2.73, 95% CI 1.12-6.69, p=0.02). Forty percent of the patients remained with symptoms after presenting COVID-19, predominantly dyspnea and/or cough (17%). CONCLUSION: In this cohort of patients with SSc, those with SSc-ILD were highly impacted by COVID-19, with a higher risk of moderate-to-severe COVID-19 infection and death.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. de Oliveira SM, Martins LVO, Lupino-Assad AP, et al. Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Semin Arthritis Rheum. 2022. PMID: 35286906. doi:10.1016/j.semarthrit.2022.151987

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。